The company specializes in interventional cardiology and endovascular technologies, with a strong focus on advanced polymer-free drug-eluting stent systems, including Cre8™ and Cre8 EVO™. Its solutions are designed to enhance procedural performance and improve long-term clinical outcomes, particularly in complex patient populations such as those with diabetes.